Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Net Income (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Net Income for 11 consecutive years, with -$62.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income fell 11.07% year-over-year to -$62.5 million, compared with a TTM value of -$155.2 million through Dec 2025, up 25.39%, and an annual FY2025 reading of -$155.2 million, up 25.39% over the prior year.
  • Net Income was -$62.5 million for Q4 2025 at Spyre Therapeutics, down from -$11.2 million in the prior quarter.
  • Across five years, Net Income topped out at -$6.7 million in Q2 2021 and bottomed at -$217.1 million in Q2 2023.
  • Average Net Income over 5 years is -$42.6 million, with a median of -$30.6 million recorded in 2022.
  • The sharpest move saw Net Income plummeted 872.45% in 2023, then soared 83.8% in 2025.
  • Year by year, Net Income stood at -$20.4 million in 2021, then increased by 8.07% to -$18.8 million in 2022, then crashed by 236.14% to -$63.2 million in 2023, then grew by 10.9% to -$56.3 million in 2024, then dropped by 11.07% to -$62.5 million in 2025.
  • Business Quant data shows Net Income for SYRE at -$62.5 million in Q4 2025, -$11.2 million in Q3 2025, and -$36.7 million in Q2 2025.